Clinical Trials Logo

Clinical Trial Summary

A prospective non-interventional study to evaluate the performance of EASYCOV IVD as point-of-care (POC) test by comparing SARS-CoV-2 positive patients with SARS-CoV-2 negative controls on paired specimens (nasopharyngeal swabs & saliva samples).


Clinical Trial Description

A prospective non-interventional study to evaluate the performance of EASYCOV IVD as point-of-care (POC) test by comparing SARS-CoV-2 positive patients with SARS-CoV-2 negative controls on paired specimens (nasopharyngeal swabs & saliva samples). The operators performing the diagnostic tests will be blinded from the RT-PCR results (i.e. participant's group will be anonymized). Participants who have been tested by an routineTurkish MOH and FDA EUA approved RT-PCR test using nasopharyngeal swabs will be included in the study to perform the EASYCOV IVD tests in a POC setting. Primary Objective: • To evaluate the performance of EasyCov IVD as a point-of-care (POC) test performed on saliva samples for the diagnosis of SARS-CoV-2 infection by comparing it to a Turkish MOH and FDA EUA approved RT-PCR test performed on nasopharyngeal samples. Secondary Objectives: • Collection and storage of saliva samples, nasopharyngeal swabs at D0 to perform future COVID-19 related research projects and validation of future generations of EASYCOV assays as well as exploratory studies to find candidate biomarkers for Covid-19. 160 participants will be included in 1:1 ratio: 80 SARS-CoV-2 positive and 80 SARS-CoV-2 negative by a Turkish MOH and FDA approved RT-PCR IVD test ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04583319
Study type Observational
Source Firalis SA
Contact
Status Completed
Phase
Start date December 12, 2020
Completion date December 30, 2021

See also
  Status Clinical Trial Phase
Completed NCT04503525 - Nutritional Assessment of Hospitalized Patients With COVID-19
Active, not recruiting NCT05870839 - Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States Phase 1
Active, not recruiting NCT05938075 - Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa Phase 1